With $300M fund, Adjuvant picks its spots among start-ups addressing global public health needs

The founders of Adjuvant Capital believe they’ve found a way to apply the VC model to global public health investing and generate returns in an area other VCs have largely eschewed.

Launched in 2019 by a pair of managing partners with experience at the Bill & Melinda Gates Foundation and the Global Health Investment Fund (GHIF), Adjuvant expects to invest its $300 million first fund in about 25 companies developing vaccines and treatments for infectious diseases, women’s health conditions and other public health challenges that particularly affect underserved populations around the globe...